For all of the frenetic acquisition and divestiture that has characterized the cardiovascular industry over the past several years, nothing seems to have matched the last two months. Certainly tremendous opportunities exist to encourage future dealing. But whereas much of the activity in cardiovascular in the past seems to have come from a euphoric sense of the promise of cardiovascular medicine, the more recent moves have an air of frustrated hopes.
In May, Heartport Inc. , once the darling of the minimally-invasive cardiac surgery market, announced a new CEO (Frank...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on In Vivo for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?